Plasma endothelin-1 in patients with prostate cancer and its clinical significance.
- Author:
Wen-quan ZHOU
1
;
Ying-hao SUN
;
Chuan-liang XU
;
Jian-ping GAO
;
Rui-ji XU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Endothelin-1; blood; Humans; Male; Prognosis; Prostatic Hyperplasia; blood; Prostatic Neoplasms; blood; Radioimmunoassay
- From: National Journal of Andrology 2006;12(4):315-322
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate plasma endothelin-1 (ET-1) level in patients with prostate cancers and its clinical significance.
METHODSPlasma ET-1 level was measured by radioimmunoassay in 31 patients of prostate cancer (23 with non-HRPC, 8 with HRPC) and 26 patients of BPH.
RESULTSCompared with each other of the ET-1 level, there were no significant difference among the BPH group,non-HRPC group and HRPC group. No significant difference was found either between bone metastasis (BM) and non- BM, between high and middling differentiation prostate cancer group, as well as in different PSA level groups (P >0.05). But the ET-1 level in low differentiation prostate cancer was notably lower than those of the high and middle respectively (P < 0.05).
CONCLUSIONTo detect plasma endothelin-1 (ET-1) level is not a useful method to evaluate the development and the prognosis of prostate cancer.
